GET DAILY SIGNALSCardio Diagnostics Holdings (CDIO): An Early Look at Epigenetics in Cardiovascular Testing
Key Takeaways
- CDIO is the Nasdaq ticker for Cardio Diagnostics Holdings, Inc., a small molecular diagnostics company developing epigenetics-based blood tests for cardiovascular disease.
- The company's core products are Epi+Gen CHD, a three-year risk assessment test, and PrecisionCHD, an early detection test for coronary heart disease.
- Cardio Diagnostics was founded in 2017, is headquartered in Chicago, Illinois, and became publicly listed through a business combination in 2022.
- As an early-stage life sciences company, it generates only minimal revenue and has reported ongoing net losses, making its financial profile high-risk.
- The company also offers HeartRisk, a software platform, and CardioInnovate360, a research-use-only solution for drug developers.
Getting Started with Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. focuses on healthcare and biotechnology, specifically developing clinical tests for cardiovascular disease, a leading cause of death worldwide. Its approach combines epigenetics—the study of gene activity influenced by lifestyle and environment—with genetic data and artificial intelligence. I follow CDIO as it offers an early-stage opportunity in precision cardiovascular medicine and non-invasive blood testing, though the company remains in the initial stages of bringing its technology to market.
Company Background and Offerings
Cardio Diagnostics Holdings was founded in 2017 and is based in Chicago, Illinois, with a CLIA-certified laboratory in Iowa City, Iowa. It went public on Nasdaq in 2022 through a business combination with a SPAC, previously known as Mana Capital Acquisition Corp. Part of its technology platform is licensed from the University of Iowa Research Foundation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company’s main products are laboratory-developed tests. These include Epi+Gen CHD, which assesses three-year risk for symptomatic coronary heart disease events like heart attacks, and PrecisionCHD, an epigenetic-genetic blood test for detecting coronary heart disease. Additional offerings include the Actionable Clinical Intelligence platform for clinician insights, HeartRisk as a SaaS cardiovascular risk tool, and CardioInnovate360 for research use by biopharmaceutical firms.
Revenue comes primarily from test sales and services through channels such as telemedicine, concierge practices, longevity clinics, risk-bearing providers, and employer groups. To date, these have produced only limited income.
Market Position
Cardio Diagnostics operates in molecular diagnostics and cardiovascular testing, competing against established firms offering cholesterol, imaging, and biomarker tests. Its edge lies in epigenetics and AI analytics, positioning the tests as complements to traditional screening. As a small, early-stage player, its competitive standing is still developing against larger, better-funded diagnostics companies.
Why Attention Turns to CDIO
Investor interest in CDIO often relates to the sizable cardiovascular disease market and the focus on precision medicine. Heart disease drives ongoing demand for earlier, personalized risk tools. The epigenetic-genetic approach paired with AI analytics provides a distinct perspective on this large market. Key areas to watch include progress on reimbursement, distribution partnerships, and scaling laboratory operations.
Risks and Key Considerations
Investing in Cardio Diagnostics involves notable risks common to early-stage biotech and diagnostics firms. The company has a short operating history, minimal revenue, and ongoing net losses while building commercialization efforts. Profitability is not guaranteed. Reimbursement remains uncertain, as securing payor coverage can take time and face unpredictable outcomes.
Regulatory oversight of laboratory-developed tests continues to evolve amid legislative discussions. Competition from larger diagnostics companies adds pressure, and sales cycles can be extended. Like many small-cap healthcare names, CDIO has seen share-price volatility and completed a reverse stock split to sustain its Nasdaq listing.
Conclusion
Cardio Diagnostics Holdings is a small, early-stage molecular diagnostics company working to introduce epigenetics-based and AI-driven blood testing into cardiovascular care. Its Epi+Gen CHD and PrecisionCHD tests, along with HeartRisk and CardioInnovate360, provide a focused technological approach in a major healthcare market. Still, minimal revenue, persistent losses, and reliance on reimbursement and commercialization milestones point to a high-risk, speculative profile. For investors, CDIO represents an early bet on precision cardiovascular medicine, with long-term prospects tied to successful adoption and scaling of its testing platform.
Enhancing Research with AI Tools
In my own analysis, I frequently use Tickeron's AI Screener to scan for stocks and ETFs based on technical indicators, fundamentals, volatility, trends, and AI signals. It helps surface ideas that fit specific strategies and supports a more structured approach to evaluating opportunities like those in the diagnostics space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CDIO in upward trend: price rose above 50-day moving average on November 10, 2026
CDIO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 22 of 24 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CDIO's RSI Indicator exited the oversold zone, 44 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CDIO as a result. In 45 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 24 of 38 cases over the following month. The odds of a continued upward trend are 63%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 53 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CDIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CDIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement